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Modification of proteins with ubiquitin (Ub) occurs through a
variety of topologically distinct Ub linkages, including Ube2W-
mediated monoubiquitylation of N-terminal alpha amines
to generate peptide-linked linear mono-Ub fusions. Protein
ubiquitylation can be reversed by the action of deubiquitylating
enzymes (DUBs), many of which show striking preference for
particular Ub linkage types. Here, we have screened for DUBs
that preferentially cleave N-terminal Ub from protein substrates
but do not act on Ub homopolymers. We show that members of
the Ub C-terminal hydrolase (UCH) family of DUBs demonstrate
this preference for N-terminal deubiquitylating activity as they
are capable of cleaving N-terminal Ub from SUMO2 and Ube2W,
while displaying no activity against any of the eight Ub linkage
types. Surprisingly, this ability to cleave Ub from SUMO2 was
100 times more efficient for UCH-L3 when we deleted the
unstructured N-terminus of SUMO2, demonstrating that UCH
enzymes can cleave Ub from structured proteins. However, UCH-
L3 could also cleave chemically synthesized isopeptide-linked
Ub from lysine 11 (K11) of SUMO2 with similar efficiency,
demonstrating that UCH DUB activity is not limited to peptide-
linked Ub. These findings advance our understanding of the
specificity of the UCH family of DUBs, which are strongly
implicated in cancer and neurodegeneration but whose substrate
preference has remained unclear. In addition, our findings suggest
that the reversal of Ube2W-mediated N-terminal ubiquitylation
may be one physiological role of UCH DUBs in vivo.
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INTRODUCTION
Conjugation of proteins with ubiquitin (Ub) is a versatile post-
translational modification that regulates a number of cellular
pathways and signalling events [1]. Modification of substrates
is achieved through the concerted actions of a series of enzymes,
starting with Ub activation by an E1 activating enzyme, transfer
to any of a number of E2 conjugating enzymes, and finally
substrate specificity is defined via an E3 ligase which recruits
the substrate and E2 to mediate Ub transfer [2].
Conjugation of Ub to a substrate lysine (K) residue can be either
a mono- or poly-ubiquitylation event, of which polyubiquitylation
can occur via isopeptide Ub chains linked through any of seven
internal K residues (K6, K11, K27, K29, K33, K48 and K63) [1],
or linear head-to-tail peptide-linked polyUb chains [3]. In addition
to these eight distinct linkage types of polymeric Ub, substrates
can also be modified by monoubiquitylation of the epsilon amino
group of a lysine residue or via the alpha amino group of the
N-terminus of the substrate to generate a linear mono-Ub fusion
protein [4–6]. An E2 conjugating enzyme responsible for the latter
type of modification is Ube2W, which can monoubiquitylate the
N-terminus of poly-SUMO2 when coupled with the E3 ligase
RNF4 [7].
The process of Ub conjugation is regulated through the catalytic
activities of deubiquitylating enzymes (DUBs), which can reverse
or edit all Ub modification types to generate free monomeric Ub
[8]. The ∼90 DUBs in the human genome can be divided into five
major classes: the ubiquitin C-terminal hydrolases (UCHs), the
ubiquitin-specific proteases (USPs), the ovarian tumour (OTU)
family, the Josephin domain family and the JAB1/MPN/MOV34
(JAMM) family [1,8]. The majority of DUBs show low linkage
specificity, including most members of the USP family which can
cleave all linkage types in vitro in a non-discriminatory manner
[1,9]. By contrast, some DUBs are highly specific for only one
type of chain linkage, for example the JAMM family member
AMSH is specific for K63 linkages, OTUB1 is specific for only
K48 linkages, and otulin only cleaves linear linked Ub chains [9–
13]. Interestingly, some DUBs are classified as pseudoDUBs, as
they contain homology with the USP superfamily but are inactive
due to the lack of an active site cysteine [14,15].
The four UCH enzymes represent an unusual family of DUBs,
as they are known to contain an active site cross-over loop that is
thought to limit substrate accessibility [16–20]. The two smallest
members of this family, UCH-L1 and UCH-L3, contain only
the core UCH domain, whereas UCH-L5 and BAP1 contain the
UCH domain and additional C-terminal extensions [21]. Although
this class of DUB was the first to be described [22], the
substrate preference of the UCH family has remained elusive.
In vitro, purified UCH enzymes show no activity against any
K-linked or linear Ub-dimers [9,23], but are able to efficiently
cleave Ub from glutathione and amines such as free lysine that
may form adventitiously [22,24]. In addition, UCH-L3 displays
Ub hydrolase activity towards the CEP52/UBA52 Ub-ribosome
precursor and Ub linearly fused to small peptides [25,26], thus
it has been assumed that UCH-L1 and UCH-L3 only cleave Ub
from substrates with small unstructured leaving groups [17,21].
The other two members of the UCH family UCH-L5 and
BAP1 contain longer inhibitory C-terminal extensions, and are
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reported to be largely inactive enzymes in vitro until association
with the proteasome and ASXL1 respectively, which relieve
their autoinhibition and permit the hydrolysis of Ub isopeptides
[27,28].
In the present study, we set out to identify DUBs that could
preferentially cleave alpha N-terminal-linked mono-Ub from
SUMO2 or Ube2W. We report that members of the UCH family
are capable of efficiently cleaving peptide-linked N-terminal
mono-Ub, while displaying no activity against Ub dimers of any
linkage type. However, UCH DUBs could also cleave isopeptide-
linked Ub from lysine 11 of SUMO2, suggesting their activity
is not strictly limited to peptide-linked N-terminal Ub. Thus, the
reversal of N-terminal ubiquitylation may be one physiological
role of UCH DUBs in vivo.
EXPERIMENTAL
Recombinant protein purification
The DUBs USP2, UCH-L1, UCH-L3, UCH-L5 and BAP1
were purified from Escherichia coli as previously described
[9]. The substrates 6xHis-Ub-SUMO2x4N11, Ub-Ube2W, Ub-
SUMO2-6xHis, Ub-SUMO21-15-6xHis, Ub-[SUMO2: 1–15]-
Ub-6xHis were purified in E. coli Rosetta (DE3) cells with
a knockout in the ElaD gene (gift from Rob Layfield) which
encodes a bacterial DUB [29]. Bacterial cells were harvested
by centrifugation and the cell pellet was resuspended in lysis
buffer (50 mM Tris/HCl, 500 mM NaCl, 10 mM imidazole and,
2 mM benzamidine) (or for Ub-Ube2W lysis: 50 mM Tris/HCl,
50 mM NaCl and 2 mM benzamidine) and lysed by sonication
(Digital Sonifier, Branson). Subsequently, Triton X100 was added
to a final concentration of 0.5% (v/v) and the sample was
centrifuged to remove any insoluble material. For Ub-SUMO2-
6xHis, Ub-SUMO21-15-6xHis and Ub-[SUMO2: 1–15]-Ub-
6xHis, the supernatant was filtered through a 0.2 μm filter
and loaded on to a n Ni2+-nitrilotriacetate (Ni-NTA)–agarose
(Qiagen) column and washed, eluted and dialysed overnight at
4 ◦C against 50 mM Tris/HCl, 150 mM NaCl and 0.5 mM tris(2-
carboxyethyl)phosphine (TCEP), pH 7.5. Purification of 6xHis-
Ub-SUMO2x4N11 was as above, followed by tobacco etch
virus (TEV) protease cleavage to remove the 6xHis tag (1 mg
of His-TEV protease per 100 mg of the fusion protein). Ub-
SUMO2x4N11 was purified by passing over an Ni-NTA–
agarose column to remove His-TEV protease and 6xHis tag.
Untagged Ub-Ube2W was purified using a Q Sepharose (GE
Healthcare) ion-exchange column and eluted with an NaCl
gradient (50-600 mM) and dialysed as above. Fractions were
concentrated using Vivaspin centrifugal concentrator (Sartorius).
Gel filtration chromatography on a HiLoad 16/60 Superdex 200
pg (for 6xHis-Ub-SUMO2x4N11) or 75 pg column (for all
other substrates) (GE Healthcare) was carried out as a final
purification step. Ub-K11-SUMO2 and Ub dimers (K6, K27, K29
and K33) were synthesized as previously described [9,30,31].
Linear Ub dimers linked via the peptide bond were expressed
as GST-fusion proteins in bacteria. The GST-tag was removed
with Prescission Protease and the dimers were purified over a
Source 15 S column and concentrated using Vivaspin 5 kDa
molecular-mass cut-off filters (Sartorius). K48-linked Ub dimers
were made enzymatically using UBE1 and GST–UBE2K. The
K63 Ub dimers were also made enzymatically using UBE1 and
UBE2N and UBE2V1. The enzymes were removed by ion-
exchange chromatography and the dimers were purified using
a Source 15 S column.
Ubiquitylation, deubiquitylation, immunodetection and
quantification
In vitro ubiquitylation of Ub-SUMO2x4N11 was carried out
at 37 ◦C for 1 h as described previously [7]. Ubiquitylated Ub-
SUMO2x4N11 was resolved from the ubiquitylation reaction
and chains purified by gel filtration on Superdex 75 medium (GE
Healthcare). For DUB assays visualized by Coomassie Blue-
stained gels, 2 μg of substrate was incubated with 100 ng/μl
DUB (1.38 μM GST-USP2 3.7 μM 6xHis-UCHL1, 1.85 μM
GST-UCHL3, 1.5 μM GST-UCHL5 or 0.9 μM GST-BAP1 at
37 ◦C for 1 h in a total volume of 10 μl in assay buffer (50 mM
Tris/HCl pH 7.6 and 5 mM DTT). Reaction products resolved
on 4–12% NuPage Bis-Tris gradient gels in MES buffer (Life
Technologies) and subsequently visualized by Coomassie Blue-
staining. Immunoblotting was carried out using anti-Ub (DAKO)
and anti-SUMO2 antibodies [32]. Densitometry analysis of gel
images was carried out using ImageJ (version 1.47; NIH).
For each protease assay, the extent of substrate cleavage was
determined and represented as a percentage of the control reaction
(USP2). A heat map presenting these data was generated using
Perseus (available from http://www.perseus-framework.org/).
Ub-rhodamine-110-Gly assays were carried out as previously
described [9].
MALDI-TOF DUB assay for establishing kinetic parameters
For the analysis by MALDI-TOF DUB assay, bovine serum
albumin (BSA), Tris and DTT were purchased from Sigma–
Aldrich. MALDI-TOF MS materials (targets, matrix and protein
calibration mixture) were from Bruker Daltonics. Screening
for activity and specificity of UCHL1, UCHL3, UCHL5 and
BAP1 against Ub-SUMO2, Ub-Ube2W, Ub-4xSUMO2N11,
Ub-SUMO21-15 and Ub-K11-SUMO2 was performed as
previously described [9]. Briefly, each UCHL family member
was incubated at different concentrations (0.02, 0.2, 2, 20 and
200 ng/μl) with each substrate (30 ng/μl). Both enzymes and
substrates were freshly prepared in the reaction buffer (40 mM
Tris/HCl, pH 7.6, 5 mM DTT, and 0.005% BSA) for each
run. The enzymes were pre-incubated in the reaction buffer
for 10 min at 30 ◦C; afterwards, the substrates were added and
the reaction mixture was incubated for 60 min at 30 ◦C. The
reaction was stopped by adding trifluoroacetic acid (TFA) to
a final concentration of 2% (v/v). Possible background due
to contamination of the substrate with Ub monomers was
measured in a reaction buffer in which the enzyme was excluded
and Ub intensities were normalized accordingly. The kinetic
constants of each enzyme were determined using the MALDI-
TOF DUB assay. For calculation of km and Vmax, each enzyme
concentration was chosen so that the reaction was linear with
a molar excess of the specific substrate over 60 min at 30 ◦C
(shaking at 850 rpm). Substrates were chosen according to
detected activity (>10%) against the DUB. All data were plotted
by SigmaPlot (version 12.5), using the enzyme kinetics tool and
the following parameters: Single Substrate Study, Michaelis–
Menten equation = Vmax × S/(km + S). The steady state
of reactions were determined by incubating a fixed amount
of enzymes (7.30 μM UCHL1, 3.82 μM UCHL3, 0.03 μM
UCHL5 and 1.87 μM BAP1) with the indicated excess of
substrate.
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Figure 1 The UCH family of DUBs cleave Ub-rhodamine-110-Gly but are inactive towards Ub dimers
(A) Domain maps of each of the UCH DUBs and the broadly active positive control USP2. (B) A 1 μg amount of each DUB was fractionated by SDS/PAGE and visualized by Coomassie Blue staining.
(C) DUB activity assessed against the artificial substrate Ub-rhodamine-110-Gly. (D) Structure of linear Ub–Ub, PDBL 2W9N [23]. DUBs were incubated with linear Ub–Ub dimers and the reaction
products were fractionated by SDS/PAGE and visualized by Coomassie Blue staining. Asterisks (*) denote the DUB in each reaction. DUB assays were carried out for 1 h at 37◦C.
RESULTS
UCH DUBs possess peptide-linked N-terminal deubiquitylating
activity
The UCH family of DUBs (UCH-L1, UCH-L3, UCH-L5 and
BAP1) (Figure 1A) are reported to be inactive against Ub dimers
of all eight linkage types [9], and therefore we reasoned that they
would be suitable candidates as DUBs that preferentially cleave
N-terminally-linked Ub. To test this, full-length versions of all
four UCH DUBs were first expressed and purified from bacteria
and visualized by Coomassie Blue-stained gel (Figure 1B). All
four UCH enzymes were active against the generic substrate
Ub-rhodamine-110-Gly (Figure 1C), but were not capable of
cleaving linear Ub dimers (Ub–Ub), while the positive control
USP2 completely cleaved this substrate (Figure 1D). To confirm
that the UCH enzymes do not act upon Ub isopeptides of any
type, Ub dimers of all linkages (K6, K11, K27, K29, K33, K48
and K63) were used as substrates against the four members
of the UCH family. USP2 was able to fully hydrolyse all Ub
dimers into free Ub, with the exception of K27 against which it
showed reduced activity (Supplementary Figure S1). However,
the UCH family enzymes were unable to hydrolyse any of the
Ub linkage types, apart from a low level activity of UCH-L3,
UCH-L5 and BAP1 against K11-linked dimers (Supplementary
Figure S1). To determine whether any of the UCH DUBs
could cleave Ub from SUMO2, we used a linear fusion of Ub
to four tandem copies of SUMO2 (Ub-SUMO2x4N11), the
result of Ube2W/RNF4-mediated N-terminal ubiquitylation of
polySUMO2 (Figure 2A) [7]. Both UCH-L3 and BAP1 utilized
this substrate generating free Ub and SUMO2x4N11, while
UCH-L1 and UCH-L5 displayed lower activity (Figure 2A). To
quantitatively evaluate the ability of UCH DUBs to cleave N-
terminal Ub from polySUMO2, we used a recently established
assay that monitors the release of free Ub by a MALDI-TOF
DUB assay [9]. Michaelis–Menten kinetics were established
for UCH-L3 (Figure 2B) and BAP1 (Figure 2C) against Ub-
SUMO2x4N11, and the catalytic efficiencies (kcat/Km) were
calculated to be 5.76 × 103 M− 1 · s− 1 for UCH-L3 and 1.45 × 104
M− 1 · s− 1 for BAP1 (Table 1). Therefore, UCH family members
possess efficient N-terminal deubiquitylation activity while
remaining inactive towards Ub dimers of all linkage types.
UCH family DUBs cleave Ub chains en bloc from polyubiquitylated
linear Ub-SUMO2x4N11
As substrates containing longer ubiquitylated chains more closely
represent physiological substrates than Ub dimers, we determined
how such substrates were utilized by UCH DUBs. To generate
substrate containing long Ub chains, Ub-SUMO2x4N11 was
ubiquitylated in vitro using RNF4 and Ube2N/Ube2V1, which
generates K63-linked Ub chains on the N-terminally linked
c© The Authors Journal compilation c© 2015 Biochemical Society
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Figure 2 The UCH DUBs can cleave Ub from the N-terminus of polySUMO2
(A) Structural representation of the Ub-SUMO2x4N11 substrate was created by using the Ub structure (PDB: 1UBQ, yellow) [46] and the SUMO2 structure (PDB: 1WM2, blue) [47] (the flexible
N-terminus of SUMO2 is represented by a blue ribbon). DUBs were incubated with Ub-SUMO2x4N11 and the reaction products were fractionated by SDS/PAGE and visualized by Coomassie Blue
staining. Asterisks (*) denote the DUB in each reaction (B) Michaelis–Menten kinetic analysis of UCH-L3 with Ub-SUMO2x4N11 as substrate. (C) Michaelis–Menten kinetic analysis of BAP1 with
Ub-SUMO2x4N11 as substrate.
Table 1 Steady-state kinetic parameters for UCH family members
V max k cat/K m
Enzyme K m (μM) (pmol·min− 1) k cat (s− 1) (M− 1·s− 1)
Ub-SUMO2
UCHL1 5.22 +− 0.49 0.03152 0.0000136 2.60
UCHL3 4.94 +− 0.70 0.2 0.000192 3.89 × 101
Ub-4xS2N11
UCHL3 1.37 +− 0.14 8.93 0.00789 5.76 × 103
BAP1 0.72 +− 0.09 5.84 0.0104 1.45 × 104
Ub-Ube2W
UCHL3 1.58 +− 0.14 7.13 0.00630 3.99 × 103
UCHL5 6.30 +− 0.93 0.9 0.10 1.59 × 104
BAP1 1.34 +− 0.20 6.65 0.0119 8.86 × 103
Ub-( 1–15) SUMO2
UCHL3 0.29 +− 0.05 1.27 0.00112 3.89 × 103
Ub-K11-SUMO2
UCHL3 0.51 +− 0.09 1.23 0.00107 2.08 × 103
Ub moiety [7] (Figure 3A). Ubiquitylated Ub-SUMO2x4N11
chains were purified by gel filtration (Supplementary Figure S2)
and used as substrate against the UCH DUBs. Reaction products
were visualized either by Coomassie Blue staining (Figure 3B,
upper panel) or by immunoblotting with antibodies to either Ub
(Figure 3B, middle panel) or SUMO2 (Figure 3B, lower panel).
Positive control USP2 cleaved all Ub linkages, resulting in the
appearance of unmodified SUMO2x4N11 substrate (Figure 3B,
top and bottom panels) and monomeric Ub (Figure 3B, top
and middle panels). However, UCH-L3, UCH-L5, BAP1 (and
to a lesser extent UCH-L1) treatment resulted in the release
of SUMO2x4N11 (Figure 3B, top and bottom panels) in the
absence of monomeric Ub release (Figure 3B, top and middle
panels). Thus, UCH DUBs can cleave the N-terminal Ub and
attached chain from Ub-SUMO2x4N11 en bloc, but do not
exert any Ub hydrolase activity towards the chains themselves.
Characterizing UCH-mediated cleavage of peptide-linked
Ub-Ube2W
To determine whether the ability to cleave N-terminal Ub was
a general property of the UCH family, we characterized DUB
activity using a second substrate. We expressed and purified
a linear fusion of Ub to Ube2W (Ub-Ube2W), the product of
Ube2W N-terminal auto-ubiquitylation [7]. UCH-L3, UCH-L5,
c© The Authors Journal compilation c© 2015 Biochemical Society
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Figure 3 UCH DUBs cleave ubiquitin chains from polyUb-SUMO2x4N11 en bloc
(A) Structural representation of the K63-polyubiquitylated substrate. K63-linked Ub chains (PDB: 2JF5, yellow) [23] and SUMO2 (PDB: 1WM2, blue) [47] (the flexible N-terminus of SUMO2 is
represented by a blue ribbon). (B) K63 polyub linked to Ub-SUMO2x4N11 was incubated with the indicated DUBs and the reaction products were fractionated by SDS/PAGE. Reaction products
were visualized by Coomassie Blue staining (upper panel), Western blotting with an antibody recognizing ubiquitin (middle panel) and Western blotting with an antibody to SUMO-2 (lower panel).
Asterisks (*) denote the DUB in each reaction.
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Figure 4 UCH mediated N-terminal deubiquitylation of Ub-Ube2W
(A) Structural representation of Ub-Ube2W substrate. Ub (PDB: 1UBQ, yellow) [46] and Ube2W (PDB: 2A7L, gold) [48]. Ub-Ube2W was incubated with the indicated UCH DUB or positive control
USP2 and the reaction products were fractionated by SDS/PAGE and visualized by Coomassie Blue staining. Asterisks (*) denote the DUB in each reaction. Michaelis–Menten kinetic analysis of
UCH-L3 (B), UCH-L5 (C) and BAP1 (D) using Ub-Ube2W as substrate.
BAP1 and positive control USP2 completely cleaved Ub from
Ube2W, as visualized by the release of free Ub and Ube2W on
a Coomassie Blue-stained gel (Figure 4A), while UCH-L1 had a
lower activity against this substrate (Figure 4A). To quantitatively
establish enzymatic parameters, we used the MALDI-TOF
DUB assay to determine Michaelis–Menten kinetics against Ub-
Ube2W for UCH-L3 (Figure 4B), UCH-L5 (Figure 4C) and BAP1
(Figure 4D). The catalytic efficiency (kcat/Km) against Ub-Ube2W
was 3.99 × 103 M− 1·s− 1 for UCH-L3, 8.86 × 103 M− 1·s− 1 for
BAP1, and the highest efficiency was 1.59 × 104 M− 1·s− 1
for UCH-L5 (Table 1). Therefore, UCH-L3, UCH-L5 and BAP1
possess a general N-terminal deubiquitylation activity.
Requirements of UCH-mediated Ub cleavage from monomeric
SUMO2
To further investigate UCH-mediated cleavage of Ub from
SUMO2, we generated a series of Ub-SUMO2 dimers to
determine UCH enzyme requirements for this reaction. Linear
Ub-SUMO2 dimers were purified and used as substrate in DUB
assays (Figure 5A), and cleavage was assessed by the release
of free Ub and free SUMO2 on Coomassie Blue-stained gels.
UCH-L1 and UCH-L3 displayed the greatest activity against
Ub-SUMO2 dimers, while UCH-L5 and BAP1 activity was
limited. We established Michaelis–Menten kinetics of UCH-L1
and UCH-L3 against Ub-SUMO2 dimers by the MALDI-TOF
DUB assay (Figure 5A), and the catalytic efficiency (kcat/Km) of
UCHL1 and UCHL3 against Ub-SUMO2 dimers were calculated
as 2.6 M− 1·s− 1 and 3.89 × 101 M− 1·s− 1 respectively (Table 1).
Since UCH DUBs cleave Ub from SUMO2 which contains an
unstructured N-terminus, but do not cleave structurally compact
Ub dimers, we wanted to determine the contribution of the
structural flexibility of the Ub conjugation site to cleavage by
UCH DUBs. Therefore, we deleted the flexible N-terminal 15
residues of SUMO2 and expressed a linear Ub-SUMO2N1-15
dimer, which comprises the Ub globular domain fused directly to
c© The Authors Journal compilation c© 2015 Biochemical Society
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Figure 5 Ub-SUMO2 substrate requirements for cleavage with UCH enzymes
(A) Linear Ub-SUMO2 substrate (structural representation above) was incubated with UCH DUBs and the reaction products were fractionated by SDS/PAGE and visualized by Coomassie Blue staining
(top panel). Michaelis–Menten kinetic analysis of UCH-L1 and UCH-L3 with Ub-SUMO2 as substrate (bottom panels). (B) Structural representation of Ub-SUMO2N1-15 used as substrate. DUB
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the SUMO2 globular domain (Figure 5B). Surprisingly, with the
exception of BAP1, we found that the UCH family all displayed
activity against this substrate (Figure 5B). Michaelis–Menten
kinetics were established for UCH-L3 against Ub-SUMO2N1-
15 by MALDI-TOF (Figure 5B). Strikingly, the catalytic
efficiency (kcat/Km) for UCHL3 against Ub-SUMO2N1-15 was
3.89 × 103 M− 1·s− 1, which is approximately 100-fold higher than
the efficiency of UCH-L3 against wild type Ub-SUMO2 dimers
(Table 1). This demonstrates that UCH enzymes can cleave Ub
from structured proteins, and suggests that structural inflexibility
does not explain why UCH enzymes do not cleave Ub dimers.
To explore this further, we created Ub dimers separated by a
flexible linker by inserting residues 1–15 from SUMO2 between
two Ub monomers to create a linear Ub-[SUMO2: 1–15]-Ub
dimer with a C-terminal 6xHis tag. Interestingly, the UCH DUBs
showed little or no ability to cleave after the first Ub, but were
capable of completely cleaving the 6xHis tag off the second Ub
(Figure 5C) (Supplementary Figure S3). Thus, UCH family DUBs
can cleave Ub from structured conjugation sites, and the close
proximity of the protomers in Ub dimers does not explain the
inability of UCH enzymes to cleave them. Finally, to determine
whether UCH enzymes possessed Ub isopeptidase activity in
addition to N-terminal peptide deubiquitylating activity, we used
a chemically synthesized isopeptide-linked Ub-SUMO2, where
SUMO2 had been site-specifically modified with Ub on lysine
11 [31] (Ub-K11-SUMO2). Interestingly, all of the UCH family
members and particularly UCH-L3 showed activity against this
substrate (Figure 5D). Michaelis–Menten enzyme kinetics were
established for UCH-L3 against Ub-K11-SUMO2 (Figure 5D)
and the catalytic efficiency (kcat/Km) was 2.11 × 103 M− 1·s− 1,
similar to that of UCH-L3 against Ub-SUMO2N1-15 (Table 1).
Thus, UCH family DUBs can efficiently cleave both isopeptide
and peptide Ub-substrate bonds, but not simple Ub–Ub bonds.
DISCUSSION
In biochemical assays, the UCH family of DUBs display no
protease activity towards Ub dimers or tetramers no matter the
linkage type (Supplementary Figure S1) [9,23]. It has been
known for some time that UCH-L1 and UCH-L3 can cleave
small adducts of Ub such as glutathione and free lysine [22,24],
and display low activity against ubiquitylated protein substrates
[33]. This has led to the suggestion that their function in vivo
is to regenerate free Ub from adventitiously generated adducts
[8,21]. In addition, UCH-L5 and BAP1 are known to be inactive
towards Ub–Ub linkages in the absence of their cellular cofactors
[27,28]. We have demonstrated that the UCH DUBs display
ability to cleave N-terminally linked and isopeptide-bond-linked
Ub from a number of protein constructs in vitro. The results are
summarized in the heat map in Figure 6. These findings imply
that UCH enzymes are specifically averse to cleaving Ub from
Ub in a simple chain, but that, with the exception of UCH-L1,
they are certainly capable of removal of Ub from large protein
substrates. N-terminal ubiquitylation has been described in vivo
[4–6], and the E2 conjugating enzyme Ube2W is capable of
synthesizing peptide bond-linked substrates in vitro [7]. This
Figure 6 Heat map of UCH DUB activity
All DUB activity is normalized to positive control USP2 and the activity of each UCH DUB is
displayed relative to this. The scale is from red (100 % activity) to black (0 % activity).
opens the possibility that one function of UCH proteases is
to cleave peptide-bond-linked Ub. However, the fact that UCH
enzymes possess low activity towards Ub–Ub peptide linkages
indicates that the modified protein cannot be Ub itself.
Kinetic analysis revealed that UCH-L3 (and to a lesser extent
UCH-L1) is capable of cleaving N-terminal peptide-linked Ub
from SUMO2x4N11 and Ube2W with a kcat/Km of 5.76 × 103
M− 1·s− 1 and 3.99 × 103 M− 1·s− 1 respectively. This is several
orders of magnitude lower than what has been reported for the
yeast UCH enzyme YUH1 against the artificial substrate Ub-
AMC (2.23 × 108 M− 1·s− 1) [17], but is in the range of what
has been reported for the OTU family DUB TRABID to cleave
K63 and K29 chains: 2.5 × 103 M− 1·s− 1and 1 × 105 M− 1·s− 1
respectively [30]. The observation that UCH enzymes can cleave
N-terminal mono-Ub from SUMO2 and Ube2W is in keeping with
previous reports showing that UCH-L3 has some activity towards
the Ub precursor protein Ub-CEP52, and a variety of fusions of Ub
to short peptides including the mutant Ub UBB + 1 [25,26,34]. It
is striking that when we ubiquitylated Ub-SUMO2x4N11 using
RNF4 and Ube2N/Ube2V1 which attaches K63-linked chains on
to the proximal Ub [7], UCH-L3, UCH-L5 and BAP1 exclusively
cleave the N-terminal linked Ub to remove the K63 chains en
bloc, completely unprocessed.
Structural studies of UCH family enzymes either in isolation or
in complex with Ub suicide probes have revealed a dynamic active
site cross-over loop that has been predicted to prevent cleavage
of Ub if conjugated to structured regions of protein [16–20,35].
This is because it has been often assumed that the leaving group
must pass through the narrow loop, which for UCH-L3 is limited
activity was assessed as in (A). Michaelis–Menten kinetic analysis of UCH-L3 with Ub-SUMO2N1-15 as substrate. (C) Structural representation of Ub-[SUMO2 1:15]-Ub-6xHis used as substrate.
DUB activity was assessed by release of free Ub and free [SUMO2:1-15]-Ub or cleavage of the 6-His tag. (D) Structural representation of isopeptide-linked Ub-K11-SUMO2 used as substrate. DUB
activity was assessed as in (A). Michaelis–Menten kinetic analysis of UCH-L3 with Ub-K11-SUMO2 as substrate. Asterisks (*) denote the DUB in each reaction. Structural representation of each
Ub-SUMO2 substrate was created by using the Ub structure (PDB: 1UBQ, yellow) [46] and the SUMO2 structure (PDB: 1WM2, blue) [47] (the flexible N-terminus of SUMO2 is represented by a blue
ribbon).
c© The Authors Journal compilation c© 2015 Biochemical Society
Characterizing the substrate specificity of the UCH family of DUBs 497
to around 15 Å (1 Å = 0.1 nm) and is thus too small to allow a
structured protein to pass [17]. Extension of this loop can render
UCH-L3 capable of hydrolysing Ub K48- and K63-linked dimers,
supporting a restrictive role of the loop in allowing structured sub-
strates access to the active site [36]. However, it seems improbable
that the leaving group could be fed completely through this loop,
given that we observe efficient removal of Ub from the N-terminus
of large, structured proteins. It is also interesting to note that UCH
enzymes would not hydrolyse Ub–Ub dimers where we inserted
the flexible 1–15 N-terminal residues of SUMO2, suggesting that
Ub dimers may be intrinsically inhibitory to UCH family DUBs.
In agreement with this idea, it has been previously reported that
K48 and K63 Ub dimers can inhibit the cleavage of Ub-AMC by
both UCHL1 and UCHL3 [37]. One possibility is that because the
active site cross-over loop is actually conformationally flexible, in
some crystal structures the loop may be stabilized in the ‘closed’
conformation. This flexibility could allow access to substrates
such as Ub-SUMO2 or Ub-Ube2W to the active site when the loop
is in the unstructured ‘open’ conformation. However, binding of
diubiquitin may induce a conformational change that stabilizes the
loop in the ‘closed’ conformation. A similar situation is evident
in the case of the SUMO proteases (SENPs). Crystal structures
of SENP1 and SENP2 both with and without substrates [38–41]
reveal that the active sites of these enzymes are occluded with an
aromatic side chain acting as a ‘lid’ to close the catalytic channel.
However, recent NMR analysis on SENP1 has revealed that Trp-
465, the aromatic residue constituting the ‘lid’ is highly mobile
in solution, thus allowing substrates to access the active site [42].
Structural studies of UCH-L3 in complex with either linear Ub–
Ub or Ub-SUMO2x4N11 will be beneficial in helping to resolve
these questions.
Our observation that UCH-L5 and BAP1 both efficiently cleave
N-terminal Ub from Ub-Ube2W and Ub-SUMO2x4N11 was
unexpected. While individual UCH domains from UCH-L5 and
BAP1 display activity towards K48 Ub dimers [43], full-length
enzymes do not cleave isopeptide-linked Ub unless associated
with their cofactors, the proteasome and ASXL1 respectively
[27,28,44]. Indeed, we find that both UCH-L5 and BAP1 in
isolation are inactive against Ub–Ub dimers of all linkage
types, but can efficiently cleave Ub-Ube2W with kcat/Km values
of 1.59 × 104 M− 1·s− 1 and 8.86 × 103 M− 1·s− 1 respectively.
Interestingly, BAP1 cleaves Ub fused to four copies of SUMO2
more efficiently than it cleaves Ub-SUMO2 dimers, and while
UCH-L5 showed little activity towards Ub fusions to SUMO2, it
efficiently cleaves Ub-Ube2W. This suggests that multiple factors
in addition to the presence of N-terminal mono-Ub influence DUB
activity. Interestingly, as UCH-L5 is a proteasome-associated
DUB, one function may be to remove N-terminal Ub from
substrates that are targeted to the proteasome by the Ub-fusion
degradation (UFD) pathway [45].
In summary, we have demonstrated that the UCH family
members efficiently cleave isopeptide- and peptide-linked Ub
from substrates but are inactive towards unbranched Ub polymers.
Despite intense research into UCH family enzymes due to their
links to neurodegenerative disease and cancer, the substrate
preference of this DUB class have remained largely elusive.
A greater understanding of the role and nature of N-terminally
ubiquitinated proteins may have bearing upon our understanding
of these functionally elusive proteases.
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